<DOC>
	<DOCNO>NCT02990481</DOCNO>
	<brief_summary>1 . To determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLTs ) TRK-950 single agent 2 . To establish dose TRK-950 recommend future phase 2 study</brief_summary>
	<brief_title>A Study TRK-950 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study first-in-human study TRK-950 patient advance solid tumor primarily design determine dose-limiting toxicity ( DLT ) maximum tolerate dose ( MTD ) TRK-950 administer via intravenous ( IV ) infusion weekly 3 week every 28 day .</detailed_description>
	<criteria>Patients histologically confirm locally advanced metastatic solid carcinoma Tumor progression receive standard/approved chemotherapy approve therapy amendable curative treatment Measurable disease per RECIST 1.1 ( primary metastasis ) New York Heart Association Class III IV , cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia , evidence ischemia ECG Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Pregnant nursing woman Treatment radiation therapy , surgery , chemotherapy , investigational therapy within four week prior study entry Unwillingness inability comply procedure require protocol Known active infection HIV , hepatitis B , hepatitis C Symptomatic brain metastasis Serious nonmalignant disease could compromise protocol objective opinion investigator and/or sponsor Patients currently receive investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>